Your SlideShare is downloading. ×
Chronic kidney disease (chronic renal failure)   pipeline review, h1 2014
Chronic kidney disease (chronic renal failure)   pipeline review, h1 2014
Chronic kidney disease (chronic renal failure)   pipeline review, h1 2014
Chronic kidney disease (chronic renal failure)   pipeline review, h1 2014
Chronic kidney disease (chronic renal failure)   pipeline review, h1 2014
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

Chronic kidney disease (chronic renal failure) pipeline review, h1 2014

125

Published on

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to …

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Published in: Business, Health & Medicine
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
125
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014 This report provides comprehensive information on the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope The report provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Chronic Renal Failure) The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Chronic Kidney Disease (Chronic Renal Failure) and enlists all their major and minor projects The report summarizes all the dormant and discontinued pipeline projects A review of the Chronic Kidney Disease (Chronic Renal Failure) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages A detailed assessment of monotherapy and combination therapy pipeline projects Coverage of the Chronic Kidney Disease (Chronic Renal Failure) pipeline on the basis of target, MoA, route of administration and molecule type Latest news and deals relating related to pipeline products Reasons to buy Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Chronic Kidney Disease (Chronic Renal Failure) Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Chronic Kidney Disease (Chronic Renal Failure) pipeline depth and focus of Indication therapeutics Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline table Of Contents table Of Contents 2 list Of Tables 7 list Of Figures 8 introduction 9 global Markets Direct Report Coverage 9 chronic Kidney Disease (chronic Renal Failure) Overview 10 therapeutics Development 11 pipeline Products For Chronic Kidney Disease (chronic Renal Failure) Overview 11 pipeline Products For Chronic Kidney Disease (chronic Renal Failure) Comparative Analysis 12 chronic Kidney Disease (chronic Renal Failure) Therapeutics Under Development By Companies 13 chronic Kidney Disease (chronic Renal Failure) Therapeutics Under Investigation By Universities/institutes 17 chronic Kidney Disease (chronic Renal Failure) Pipeline Products Glance 18 late Stage Products 18 clinical Stage Products 19 early Stage Products 20 chronic Kidney Disease (chronic Renal Failure) Products Under Development By Companies 21 chronic Kidney Disease (chronic Renal Failure) Products Under Investigation By Universities/institutes 23 chronic Kidney Disease (chronic Renal Failure) Companies Involved In Therapeutics Development 24 sanofi 24 astrazeneca Plc 25 eli Lilly And Company 26 quark Pharmaceuticals, Inc. 27 opko Health, Inc. 28 toray Industries, Inc. 29 evotec Ag 30 la Jolla Pharmaceutical Company 31 alexion Pharmaceuticals, Inc. 32 acceleron Pharma, Inc. 33 nippon Zoki Pharmaceutical Co., Ltd. 34 catabasis Pharmaceuticals, Inc. 35 angion Biomedica Corp. 36 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014
  • 2. thrasos, Inc. 37 concert Pharmaceuticals, Inc. 38 cormedix, Inc. 39 vitae Pharmaceuticals, Inc. 40 stelic Institute & Co. 41 sorbent Therapeutics, Inc. 42 vicore Pharma Ab 43 invasc Therapeutics, Inc. 44 sphaera Pharma Pvt. Ltd. 45 multi Gene Vascular Systems Ltd 46 chiasma, Inc. 47 chronic Kidney Disease (chronic Renal Failure) Therapeutics Assessment 48 assessment By Monotherapy Products 48 assessment By Combination Products 49 assessment By Target 50 assessment By Mechanism Of Action 53 assessment By Route Of Administration 56 assessment By Molecule Type 58 drug Profiles 61 beraprost Sodium La - Drug Profile 61 product Description 61 mechanism Of Action 61 r&d Progress 61 sotatercept - Drug Profile 64 product Description 64 mechanism Of Action 64 r&d Progress 64 eculizumab - Drug Profile 66 product Description 66 mechanism Of Action 66 r&d Progress 66 gcs-100 - Drug Profile 69 product Description 69 mechanism Of Action 69 r&d Progress 69 deferiprone - Drug Profile 71 product Description 71 mechanism Of Action 71 r&d Progress 71 (losartan Potassium + Alpha Lipoic Acid) - Drug Profile 73 product Description 73 mechanism Of Action 73 r&d Progress 73 tenapanor - Drug Profile 74 product Description 74 mechanism Of Action 74 r&d Progress 74 ly-3016859 - Drug Profile 76 product Description 76 mechanism Of Action 76 r&d Progress 76 enalapril Maleate - Drug Profile 77 product Description 77 mechanism Of Action 77 r&d Progress 77 sar-407899 - Drug Profile 78 product Description 78 mechanism Of Action 78 r&d Progress 78 vtp-27999 - Drug Profile 79 product Description 79 mechanism Of Action 79 r&d Progress 79 clp-1004 - Drug Profile 81 product Description 81 mechanism Of Action 81 r&d Progress 81 ctp-499 - Drug Profile 82 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014
  • 3. product Description 82 mechanism Of Action 82 r&d Progress 82 small Molecule For Chronic Kidney Disease - Drug Profile 84 product Description 84 mechanism Of Action 84 r&d Progress 84 small Molecule For Chronic Kidney Disease - Drug Profile 85 product Description 85 mechanism Of Action 85 r&d Progress 85 ghrelin - Drug Profile 86 product Description 86 mechanism Of Action 86 r&d Progress 86 thr-123 - Drug Profile 87 product Description 87 mechanism Of Action 87 r&d Progress 87 c-21 - Drug Profile 88 product Description 88 mechanism Of Action 88 r&d Progress 88 cat-4000 Series - Drug Profile 90 product Description 90 mechanism Of Action 90 r&d Progress 90 ang-3070 - Drug Profile 91 product Description 91 mechanism Of Action 91 r&d Progress 91 multigenegraft - Drug Profile 92 product Description 92 mechanism Of Action 92 r&d Progress 92 cxa-10 - Drug Profile 93 product Description 93 mechanism Of Action 93 r&d Progress 93 cat-4001 - Drug Profile 94 product Description 94 mechanism Of Action 94 r&d Progress 94 sphk2 Program - Drug Profile 95 product Description 95 mechanism Of Action 95 r&d Progress 95 tpx-200 - Drug Profile 96 product Description 96 mechanism Of Action 96 r&d Progress 96 nz-419 - Drug Profile 97 product Description 97 mechanism Of Action 97 r&d Progress 97 small Molecule To Inhibit Epoxide Hydrolase For Chronic Kidney Disease - Drug Profile 98 product Description 98 mechanism Of Action 98 r&d Progress 98 vida-5 - Drug Profile 99 product Description 99 mechanism Of Action 99 r&d Progress 99 sirna For Chronic Diseases - Drug Profile 101 product Description 101 mechanism Of Action 101 r&d Progress 101 stnm-310 - Drug Profile 102 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014
  • 4. product Description 102 mechanism Of Action 102 r&d Progress 102 ang-4011 - Drug Profile 103 product Description 103 mechanism Of Action 103 r&d Progress 103 drug For Kidney Diseases - Drug Profile 104 product Description 104 mechanism Of Action 104 r&d Progress 104 chronic Kidney Disease Program - Drug Profile 105 product Description 105 mechanism Of Action 105 r&d Progress 105 drugs To Inhibit Cyp24 For Ckd And Pre-ckd - Drug Profile 106 product Description 106 mechanism Of Action 106 r&d Progress 106 small Molecules For Chronic Kidney Disease - Drug Profile 107 product Description 107 mechanism Of Action 107 r&d Progress 107 small Molecules For Chronic Kidney Disease - Drug Profile 108 product Description 108 mechanism Of Action 108 r&d Progress 108 fluorophosphophloretin - Drug Profile 109 product Description 109 mechanism Of Action 109 r&d Progress 109 brn-1889 - Drug Profile 110 product Description 110 mechanism Of Action 110 r&d Progress 110 chronic Kidney Disease (chronic Renal Failure) Recent Pipeline Updates 111 chronic Kidney Disease (chronic Renal Failure) Dormant Projects 129 chronic Kidney Disease (chronic Renal Failure) Discontinued Products 130 chronic Kidney Disease (chronic Renal Failure) Product Development Milestones 131 featured News & Press Releases 131 mar 10, 2014: La Jolla Pharmaceutical Company Reports Positive, Top-line Results From Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 131 feb 21, 2014: La Jolla Pharmaceutical Company Announces Final Dosing In Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 132 jan 15, 2014: La Jolla Pharmaceutical Company Announces The Start Of A Phase 2 Extension Study Of Gcs-100 In Chronic Kidney Disease 132 dec 16, 2013: La Jolla Pharmaceutical Company Announces Complete Enrollment Of Phase 2 Clinical Trial Of Gcs-100 In Chronic Kidney Disease 133 nov 20, 2013: Kyowa Hakko Kirin Announces The Development Status Of Bardoxolone Methyl (rta 402) In Patients With Chronic Kidney Disease And Type 2 Diabetes In Japan 134 nov 15, 2013: Opko Completes Patient Recruitment In First Phase 3 Trial Of Rayaldy 134 sep 24, 2013: Phase 3 Data On Heplisav In Adults Aged 40-70 And Patients With Chronic Kidney Disease Published In Vaccine 135 sep 03, 2013: Rockwell Medical To Discuss Top-line Results From Final Sfp Phase 3 Efficacy Study Cruise-2 135 sep 02, 2013: New Protocols To Accelerate Iv Erepoxen Trials In India 136 aug 06, 2013: La Jolla Pharmaceutical Company Abstract Accepted For The American Society Of Nephrology Kidney Week 2013 136 appendix 137 methodology 137 coverage 137 secondary Research 137 primary Research 137 expert Panel Validation 137 contact Us 138 disclaimer 138 ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price. Contact: Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014
  • 5. M/s Sheela, 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-997-4948 Email: sales@researchmoz.us Website: http://www.researchmoz.us/ Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2014

×